
|Videos|July 7, 2017
Results for the Combination of Ublituximab and Ibrutinib in CLL
Author(s)Jeff Sharman, MD
Jeff Sharman, MD, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).




















